Benoît Lhermitte

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma

Roger Stupp, Sophie Taillibert, Andrew A. Kanner et al. · JAMA · 2017 · 2.5K citations · Full text

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

Annika Malmström, Bjørn Henning Grønberg, Christine Marosi et al. · The Lancet Oncology · 2012 · 1.2K citations

Neuro-oncology, Radiation Medicine, Radiation Therapy +8

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

Roger Stupp, Monika E. Hegi, Thierry Gorlia et al. · The Lancet Oncology · 2014 · 1K citations

Neuro-oncology, Glioma, Medicine +9

A colorectal cancer classification system that associates cellular phenotype and responses to therapy

Anguraj Sadanandam, Costas A. Lyssiotis, Krisztián Homicskó et al. · Nature Medicine · 2013 · 954 citations · Full text

Tumor Biology, Oncology, Tumor Heterogeneity +9

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma

Roger Stupp, Sophie Taillibert, Andrew A. Kanner et al. · Zurich Open Repository and Archive (University of Zurich) · 2017 · 641 citations

Neuro-oncology, Oncology, Medicine +9